3SBio Inc. (HKG:1530)

Market Cap	39.21B +45.3%
Revenue (ttm)	19.69B +94.3%
Net Income	9.44B +305.8%
EPS	3.82 +303.6%
Shares Out	2.50B
PE Ratio	4.11
Forward PE	12.34
Dividend	0.25 (1.59%)
Ex-Dividend Date	Jul 21, 2026

Volume	34,866,147
Open	16.20
Previous Close	15.98
Day's Range	15.50 - 16.49
52-Week Range	15.54 - 36.80
Beta	0.47
Analysts	Strong Buy
Price Target	37.57 (+139.61%)
Earnings Date	Aug 21, 2026

About 3SBio

3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People’s Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thrombocytopenia. It also provides EPIAO for indications, such as the treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 6,109
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1530

Financial Performance

In 2025, 3SBio's revenue was 17.70 billion, an increase of 94.29% compared to the previous year's 9.11 billion. Earnings were 8.48 billion, an increase of 305.78%.

Financial numbers in CNY

Analyst Summary

According to 14 analysts, the average rating for 1530 stock is "Strong Buy." The 12-month stock price target is $37.57, which is an increase of 139.61% from the latest price.

Price Target

$37.57

(139.61% upside)

Analyst Consensus: Strong Buy